In vitro growth-inhibitory effects of Portulaca oleracea L. formulation on intestinal pathogens

Sae Okuda1, Takeaki Wajima1*, Tetsuya Yamada2, Hidemasa Nakaminami1, Hideaki Ikoshi2 and Norihisa Noguchi1

Abstract

Introduction. Empirical evidence suggests that Portulaca oleracea L. treats enteric infections, including dysentery, cholera, and acute infectious gastroenteritis.

Aim. The aim of this study is to clarify the growth-inhibitory effects of Portulaca oleracea L. extract against 56 strains of intestinal pathogens.

Methodology. ‘Gogyo-so-cha (GSC)’ was used as the P. oleracea L. formulation. A growth curve analysis was used to measure the growth-inhibitory effects of GSC, and Shiga toxin induction was measured using the latex agglutination test.

Results. GSC demonstrated strong bactericidal effects against Shigella dysenteriae and Vibrio cholerae strains from various isolates. GSC demonstrated weak or no bactericidal effects against intestinal commensal bacteria, including Enterococcus spp. and Escherichia coli. GSC did not induce Shigella toxins.

Conclusion. GSC significantly inhibited the growth of intestinal pathogens, including S. dysenteriae and V. cholerae, without adversely affecting the intestinal flora, supporting the usage of GSC in traditional Chinese medicine. Taken together, GSC would be of immense value in the developing world, where diarrhoeal infectious diseases continue to pose a major health risk.

INTRODUCTION

Portulaca oleracea L. is a perennial plant that is ubiquitously distributed from the tropical zone to the temperate zone and is marketed as a health food in Japan under the name Gogyo-so-cha. In traditional Chinese medicine, P. oleracea extract has been used empirically for the treatment of infectious diseases, particularly intestinal infections, including dysentery, cholera, and acute infectious gastroenteritis [1].

Dysentery and cholera are rare in developed countries owing to high standards of sanitation and education regarding hygiene but persist as serious health problems in developing countries, especially in Southeast Asia [2]. Epidemiological studies demonstrated that the number of dysentery patients exceeded 600000 in Bangladesh, China, Pakistan, Indonesia, Vietnam, and Thailand, and most of these patients were children under 5 years of age [2]. The World Health Organization (WHO) estimated the annual incidence of cholera to be between 1.3 million and 4 million, with there being between 2100 and 143000 deaths per year [3].

Dysentery is usually treated with antimicrobial agents. Although these agents are effective, they can induce the release of intracellular toxins and toxin gene expression [4, 5]. Antimicrobial therapy is not suitable for cholera, and oral replacement of fluids is the treatment of choice [6]. An effective therapeutic agent that does not cause toxin release is required; however, the development of novel antimicrobial agents is on the decline [7].

Randomised controlled trials reported success regarding the use of probiotics for cholera prophylaxis [8]. There are also reports indicating that bacteriostatic drugs are effective for the treatment of intestinal infections [9]. These results suggest that agents with milder actions may be more efficacious than standard treatments for enteric infections.

Received 07 December 2020; Accepted 05 February 2021
Author affiliations: 1Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; 2Department of Traditional Chinese Medicine, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
*Correspondence: Takeaki Wajima, twajima@toyaku.ac.jp
Keywords: Portulaca oleracea L.; Shigella dysenteriae; Vibrio cholerae; Cholera; Dysentery.
Abbreviations: c.f.u., colony forming unit; EHEC, enterohaemorrhagic E. coli; ESBL, extended spectrum β-lactamase; ETEC, enterotoxigenic E. coli; GSC, Gogyo-so-cha; LRV, log reduction value; MBL, metallo β-lactamase.
000208 © 2021 The Authors
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
We thus investigated the antimicrobial efficacy of the *P. oleracea* formulation, Gogyo-so-cha (GSC), against various intestinal pathogens to determine its usefulness as a therapeutic agent.

**METHODS**

**Bacterial strains, culture conditions, and chemicals**

A total of 56 bacterial strains from 20 species were investigated that included control strains and various isolates (Table 1). All strains, except anaerobic bacteria, *Enterococcus* spp., and *Candida albicans*, were cultured at 35°C in Mueller–Hinton broth and agar (Oxoid) were used. For anaerobic bacteria, modified Gifu Anaerobic Medium (GAM) broth and agar (Nissui Pharmaceutical, Tokyo, Japan) were used. For *Enterococcus* spp. and *Candida albicans*, brain heart infusion (BHI) broth and agar (Oxoid) were used. Anaerobic bacteria were cultured under the recommended conditions. Anti-microbial susceptibility and inhibitory effects against these strains were confirmed by previous study [10, 11].

GSC (Lot, 2020.1/FCA IK; Iskra Co. Ltd., Tokyo, Japan) was employed as the *P. oleracea* formulation and contained 3 g (dry weight) of condensed *P. oleracea* extract per gram and no other bioactive components.

**Evaluation of growth-inhibitory effect**

The growth-inhibitory effect was measured as previously described [11]. Tested strains were suspended in the appropriate media, as described above, and cultured overnight at 35°C with shaking. The bacterial concentration was adjusted to 10^3 c.f.u. ml⁻¹ with the same medium, and cultures were incubated at 35°C with shaking in the presence or absence of GSC (20 mg ml⁻¹). After 1-, 2-, 4-, and 6h incubation periods, the cultures were diluted with PBS and spread onto appropriate agar media. On the following day, colony number was counted, and bacterial concentration (c.f.u. ml⁻¹) was calculated. In cases where anaerobic bacteria and fungi were assessed, c.f.u. ml⁻¹ was also calculated after 24 h of incubation. For bacteria that were inhibited by GSC, assays were performed at least three times on different days. The log reduction value (LRV) was calculated as described below:

\[ \text{LRV} = \log \left( \frac{\text{c.f.u. in the absence of GSC}}{\text{c.f.u. in the presence of GSC}} \right) \]

**Evaluation of the effect of GSC on Shiga toxin production**

*Shigella dysenteriae* BCH 518 was cultured overnight and then diluted with fresh LB (1:100) and cultured with shaking for 6 h at 35°C. GSC was then added at a concentration of 20 mg ml⁻¹. For comparison, 5 mg ml⁻¹ levofloxacin (L0193; Lot, 8NMZJ-TS; Tokyo Chemical Industry, Tokyo, Japan) and 5000 units ml⁻¹ polymyxin B (167–11691; Lot, LAJ6280; Wako, Osaka, Japan) were also added to *S. dysenteriae* solutions as experimental controls. The mixtures were incubated for 30 min at 35°C with shaking. The bacteria were removed by centrifuging at 4000 g for 20 min. Toxin level in the supernatant was quantified using a Shiga Bacterial Toxin Detection Kit VTEC-RPLA ‘Seiken’ (DENKA SEIKEN, Tokyo, Japan).

**Statistical analysis**

Differences in growth-inhibitory effect and Shiga toxin production were evaluated in the presence and absence of GSC by Welch’s *t*-test. *P*<0.05 was considered significant.

**RESULTS AND DISCUSSION**

**Growth-inhibitory effects of GSC against various bacteria and fungi**

We measured growth-inhibitory effects of GSC against various bacteria and fungi using the methods that were confirmed by previous studies [10, 11] (Fig. 1). GSC significantly reduced the growth rates of *Bacillus subtilis*, *Escherichia coli*, *Citrobacter freundii*, *Shigella boydii*, *Shigella sonnei*, and *Salmonella Enteritidis* (*P*<0.01 for all) and inhibited the growth of *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Vibrio cholerae*, and *Shigella dysenteriae*. GSC did not inhibit *Enterococcus faecalis*, *Enterococcus faecium*, *Clostridioides difficile*, *Klebsiella oxytoca*, *Serratia marcescens*, *Enterobacter cloacae*, *Bacteroides fragilis*, and *Candida albicans*. These data demonstrated GSC’s inhibitory effects against intestinal pathogens, supporting its use as an empirical therapy.

**Growth-inhibitory effects of GSC against intestinal pathogens**

We used clinical isolates, including antimicrobial-resistant strains, to confirm the growth-inhibitory effects of GSC against intestinal pathogens (Fig. 2). The growth rates of all tested strains of *V. cholerae* (*n*=5) and *S. dysenteriae* (*n*=4) were inhibited significantly. GSC weakly suppressed the growth of *S. flexneri*. However, comparing the CFUs at 24 h after incubation, there was no significant changes regardless of the presence or absence of GSC (data not shown), suggested that GSC temporary delayed *S. flexneri*. These data suggested that the growth-inhibitory effects of GSC were different for *Shigella* spp. We investigated the effects of GSC against pathogenic *E. coli*, including enterotoxigenic (ETEC), enterohaemorrhagic *E. coli* (EHEC), and expanded spectrum β-lactamase (ESBL)-producing *E. coli*. The growth of ESBL-producing clinical isolates was inhibited significantly by GSC, although no inhibitory effects against EHEC and ETEC were observed.

The growth rates of metallo β-lactamase (MBL)-producing and ESBL-producing *K. pneumoniae* clinical isolates (*n*=8) were reduced significantly by GSC. Additionally, the growth rates of *K. pneumoniae* and *P. mirabilis* clinical isolates, including ESBL producers (*n*=4) and a *C. freundii* clinical isolate (MBL producer), were also inhibited. There was no growth inhibition seen for *E. cloacae* clinical isolates.

The cause of variation in antimicrobial effects among species in the *Enterobacteriaceae* family remains unclear. *P. oleracea* contains many components, including flavonoids, alkaloids, fatty acids, terpenoids, and polysaccharides [12, 13].
Table 1. Bacterial and fungal strains used in this study

| Species                   | Strain      | Species       | Strain      |
|---------------------------|-------------|---------------|-------------|
| **Gram-positive**         |             |               |             |
| *Staphylococcus aureus*   | N315*       | *Bacillus subtilis* | ATCC6633*   |
| *Enterococcus faecalis*   | JCM5803*    | *Enterococcus faecium* | JCM5804*    |
| *Clostridiales difficile* | JCM11019*   |               |             |
| **Gram-negative**         |             | *Enterobacter cloaca* | JCM1232*    |
| *Escherichia coli*        | ATCC25922*  |               |             |
| Str 3860 (ESBL producer)† | Str 3863 (ESBL producer)† | Str 3865 (ESBL producer)† | Str 3866 (ESBL producer)† |
| E96164 (O157: H7)         | Citrobacter freundii | Str 4000 (MBL producer)** | Str 4009 (MBL producer)** |
| EDL933 (O157: H7)         |               | Str 4006 (MBL producer)** |               |
| 4266 (LT • ST producer)   | *Bacteroides fragilis* | JCM1296*    |             |
| 86–24 (O157: H7)          | Vibrio cholerae | RIMD2203098 (O1, Ogawa)* |             |
| *Klebsiella pneumoniae*   | ATCC13883*  |               |             |
| Str 1449 (MBL producer)†  | Str 3860 (ESBL producer)† | Str 3740 (ESBL producer)† | Str 3811 (ESBL producer)† |
| Str 3333 (MBL producer)†  | S69B (O1, classical) | Str 3750 (ESBL producer)† |               |
| Str 3740 (ESBL producer)† | SG24 (O139) | Str 3750 (ESBL producer)† |             |
| Str 3750 (ESBL producer)† | N16961 (O1, Eltor) | Str 3750 (ESBL producer)† | Shigella dysenteriae 4379–90* |
| Str 3859 (ESBL producer)† | GTC00786T   |               |             |
| *Klebsiella oxytoca*      | JCM1665*    |               |             |
| Str 3789 (ESBL producer)† | Str 3790 (ESBL producer)† | Str 3811 (ESBL producer)† | Shigella flexneri GTC00780T* |
| Str 3790 (ESBL producer)† | BCH518       |               |             |
| Str 3811 (ESBL producer)† |               |               |             |
| *Proteus mirabilis*       | JCM1669*    |               |             |
| Str 3232                  | Str 3830 (ESBL producer)† | Str 3831 (ESBL producer)† | Str 3858 (ESBL producer)† |
| Str 3830 (ESBL producer)† | Shigella boydii | Str 3831 (ESBL producer)† | Shigella sonnei GTC00781T* |
| Str 3831 (ESBL producer)† |               | Str 3858 (ESBL producer)† |               |
| Str 3811 (ESBL producer)† |               |               |             |
| *Serratia marcescens*     | JCM1239*    |               |             |
| Str 3811 (ESBL producer)† |               |               |             |
| Str 3858 (ESBL producer)† |               |               |             |
| Str 3858 (ESBL producer)† |               |               |             |
| *Fungi*                   |               | *Salmonella Enteritidis* | PTL-93–417* |
| *Candida albicans*        | ATCC10231*  |               |             |

*These strains are either type strains or susceptible control strains.
†Clinical isolates from Tokyo medical university Hachioji medical center.
ESBL, Extended spectrum β-lactamase; MBL, metallo-β-lactamase; LT, heat-labile enterotoxin; ST, heat-stable enterotoxin.
Fig. 1. The growth-inhibitory effect of Gogyo-so-cha for the type or susceptibility test standard strains of various microorganisms (a), Gram-positive bacteria; (b), Gram-negative bacteria; (c), fungi. Data are presented as mean±SD and level of significance is indicated as *P<0.05, **P<0.01, ***P<0.001.
Previously, purified portulacerebrosides, novel cerebroside compounds isolated from Portulaca oleracea L., were reported to exert antimicrobial activity against enterobacteria [14]. The interactions between the many compounds comprising GSC may account for variations in its antimicrobial effects.

Collectively, our data indicated that GSC has strong bactericidal growth-inhibitory activity against S. dysenteriae and V. cholerae strains from various clinical isolates. However, GSC showed no inhibitory effect (or weak or temporary effect) against commensal bacteria, including E. faecalis, E. faecium, E. coli, and K. oxytoca.

The pH value of Mueller–Hinton medium was 7.18 without GSC and 6.68 with GSC. Since pH significantly affects bacterial growth, we performed a growth-inhibition assay using low-pH (pH 6.68) Mueller–Hinton medium (data not shown). The growth-inhibitory effect on E. coli, S. dysenteriae, and V. cholerae in the pH 6.68 Mueller–Hinton medium remained unchanged, suggesting growth
inhibition was attributable to GSC and not the decrease in pH caused by GSC addition to Mueller–Hinton medium.

**Comparison of bacterial number LRV**

The LRV for each bacterial species was calculated at 6 and 24 h to evaluate the antimicrobial spectrum of GSC and compare bacterial numbers between species (Fig. 3). The LRVs for *V. cholerae* and *S. dysenteriae* were found to be greater than 3, showing the potent bactericidal action of GSC.

**Evaluation of toxin-inducing ability**

In general, a large portion of the Shiga toxin was found on the periplasm of *S. dysenteriae* rather than on its outer membrane. Some antimicrobial agents can cause bacteria to release intracellular toxins via cell lysis or induce toxin production via toxin-encoding bacteriophages, and this may negatively impact recovery [4, 15, 16]. To evaluate whether GSC induced bacteria to release or produce toxins, we compared the amount of toxin in the medium with polymyxin B, levofloxacin, or GSC (Fig. 4). When toxin production in the presence of polymyxin B and levofloxacin were assayed, toxins in the media were found to be present at more than 128 folds and 64 folds, respectively. However, when GSC was assayed, toxins were found to be present at up to 32 folds, and no difference between its activity and that of the control (no antimicrobial agent) was seen, indicating that GSC may not possess toxin-inducing ability.
CONCLUSION

Our data indicated that GSC exerts strong antimicrobial effects against intestinal pathogens, including S. dysenteriae and V. cholerae. Moreover, it showed no inhibitory effect (or only a weak effect) on major commensal bacteria such as E. faecalis, E. faecium, E. coli, and K. oxytoca. Considering the fact that antimicrobial agents with spectra as broad as that of GSC have not been identified, GSC may be acting through a novel antimicrobial mechanism. Thus, our data support the empirical usage of GSC in intestinal infections.

Furthermore, GSC did not induce toxin production. Antimicrobial agents are known to induce the release of toxins from bacteria by disrupting their cell walls or by activating toxin-encoding phages [15, 16]. These data suggest that GSC inhibits intestinal pathogens without inducing toxin production.

This study has a major limitation. As this Portulaca oleracea L. formulation includes many components, the actual active component is still unknown [13]. Moreover, the activities of these compounds sometimes disappear during the isolation and extraction of the active components [17]. Future studies should thus focus on identifying the bioactive compounds in Portulaca oleracea L. formulations. However, our present data provide sufficient evidence to support the empirical use of GSC in infectious diseases.

Collectively, these findings indicate that GSC may be an effective treatment option for diarrhoea and a promising lead compound for the development of novel antimicrobial agents.

References
1. Jialin T. Chinese Materia Medica. China: People’s Medical Publishing House; 2007.
2. von Seidlin L, Kim DR, Ali M, Lee H, Wang X et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006;3:e353.
3. WHO. Who cholera fact sheet, 2017.
4. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli 0104:H4 strain. Antimicrob Agents Chemother 2012;56:3277–3282.
5. Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages—genomes in motion. Int J Med Microbiol 2004;294:115–121.
6. Atia A, Buchman AL. Treatment of cholera-like diarrhoea with oral rehydration. Ann Trop Med Parasitol 2010;104:465–474.
7. IDSA. Antibiotic resistance fact sheet, 2013.
8. Sur D, Manna B, Niyogi SK, Ramamurthy T, Palit A et al. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol Infect 2011;139:919–926.
9. Murakami J, Kishi K, Hirai K, Hiramatsu K, Yamasaki T et al. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli 0157:H7 in vitro. Int J Antimicrob Agents 2000;15:103–109.
10. Seyama S, Nishioka H, Nakamihama H, Nakase K, Wajima T et al. Evaluation of in vitro bactericidal activity of 1.5% Olanexidine gluconate, a novel biguanide antiaseptic agent. Biol Pharm Bull 2011;32:512–515.
11. Yamada T, Wajima T, Nakamihama H, Kobayashi K, Ikoshi H et al. The modified Gingyo-san, a Chinese herbal medicine, has direct antibacterial effects against respiratory pathogens. BMC Complement Altern Med 2016;16:463.
12. Rahimi VB, Ajam F, Rakshshandeh H, Askari VR. A pharmacological review on Portulaca oleracea L.: focusing on anti-inflammatory, anti-oxidant, immuno-modulatory and antitumor activities. J Pharmacopuncture 2019;22:7–15.
13. Zhou Y-X, Xin H-L, Rahman K, Wang S-J, Peng C et al. Portulaca oleracea L.: a review of phytochemistry and pharmacological effects. Biomed Res Int 2015;2015:925631–.
14. Lei X, Li J, Liu B, Zhang N, Liu H. Separation and Identification of Four New Compounds with Antibacterial Activity from Portulaca oleracea L. Molecules 2015;20:16375–16387.
15. Jackson JJ, Kropp H. Beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific cefazidime. J Infect Dis 1992;165:1033–1041.
16. Ochoa TJ, Chen J, Walker CM, Gonzales E, Cleary TG. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 2007;51:2837–2841.
17. Wajima T, Kinugawa R, Yamada T, Ikoshi H, Noguchi N. Panax notoginseng extract possesses significant antibacterial activity against pathogenic streptococci. Pharmacology 2019;103:221–227.

Funding information
The authors received no specific grant from any funding agency.

Acknowledgement
We greatly appreciated to Dr Takashi Hamabata (National Centre for Global Health and Medicine), Dr Takeshi Fujii and Mr. Yutaka Nasu (Tokyo Medical University Hachioji Medical Centre) for kindly providing bacterial strains.

Author contributions
T. W., H. N. and N. N., designed the experiments. S. O., performed the experiments. S. O., T. Y., T. W., H. N., H. I. and N. N., analysed the data. S. O. and T. W., wrote the draft manuscript. T. W. and N. N., revised the manuscript.

Conflicts of interest
The authors declare that there are no conflicts of interest.

Ethical statement
All authors read and approved the manuscript.

Five reasons to publish your next article with a Microbiology Society journal
1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.